Journal of Antimicrobial Chemotherapy, Vol 40, 573-577, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
JM Andrews, D Honeybourne, G Jevons, NP Brenwald, B Cunningham and R Wise
Concentrations of levofloxacin were measured in bronchial biopsies,
alveolar macrophages (AM), epithelial lining fluid (ELF) and serum
following a single oral dose. Concentrations were measured by a
microbiological assay method. A total of 35 patients undergoing fibre-
optic bronchoscopy were studied. Mean serum, AM, ELF and biopsy
concentrations were as follows. 0.5 h: 4.73 mg/L, 19.1 mg/L, 4.74 mg/L and
4.3 mg/kg; 1 h: 6.6 mg/L, 32.5 mg/L, 10.8 mg/L and 8.3 mg/kg; 2 h: 4.9
mg/L, 41.9 mg/L, 9.0 mg/L and 6.5 mg/kg; 4 h: 4.1 mg/L, 27.7 mg/L, 10.9
mg/L and 6.0 mg/kg; and 6-8 h: 4.0 mg/L, 38.4 mg/L, 9.6 mg/L and 4.0 mg/kg
respectively. Mean serum and AM concentrations at 12-24 h were 1.2 and 13.9
mg/L respectively (concentrations in biopsy and ELF were only measurable in
three of the six patients). These concentrations exceed the MIC90s of the
common respiratory pathogens, Haemophilus influenzae (0.015 mg/L),
Moraxella catarrhalis (0.06 mg/L) and Streptococcus pneumoniae (1 mg/L) and
suggest that levofloxacin should be efficacious in the treatment of
community- and hospital- acquired respiratory infection.
ORIGINAL ARTICLES
Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Kiem and J. J. Schentag Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gotfried, J.-P. Shaw, B. M. Benton, K. M. Krause, M. R. Goldberg, M. M. Kitt, and S. L. Barriere Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics Antimicrob. Agents Chemother., January 1, 2008; 52(1): 92 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Noreddin, V. L. Haynes, and G. G. Zhanel Pharmacokinetics and Pharmacodynamics of the New Quinolones Journal of Pharmacy Practice, December 1, 2005; 18(6): 432 - 443. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Cazzola, M. G. Matera, G. Donnarumma, M. A. Tufano, A. Sanduzzi, F. Marchetti, and F. Blasi Pharmacodynamics of Levofloxacin in Patients With Acute Exacerbation of Chronic Bronchitis Chest, October 1, 2005; 128(4): 2093 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Smith, A. L. Baltch, W. J. Ritz, A. N. Carpenter, T. A. Halse, and L. H. Bopp In Vitro Activities of Garenoxacin and Levofloxacin against Chlamydia pneumoniae Are Not Affected by Presence of Mycoplasma DNA Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2081 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Capitano, H. M. Mattoes, E. Shore, A. O'Brien, S. Braman, C. Sutherland, and D. P. Nicolau Steady-State Intrapulmonary Concentrations of Moxifloxacin, Levofloxacin, and Azithromycin in Older Adults Chest, March 1, 2004; 125(3): 965 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamazaki, S. Ogura, A. Ishizaka, T. Oh-hara, and M. Nishimura Bronchoscopic Microsampling Method for Measuring Drug Concentration in Epithelial Lining Fluid Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1304 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Rodvold, L. H. Danziger, and M. H. Gotfried Steady-State Plasma and Bronchopulmonary Concentrations of Intravenous Levofloxacin and Azithromycin in Healthy Adults Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2450 - 2457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Boswell, J. M. Andrews, G. Jevons, and R. Wise Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance J. Antimicrob. Chemother., October 1, 2002; 50(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kutlin, P. M. Roblin, and M. R. Hammerschlag Effect of Prolonged Treatment with Azithromycin, Clarithromycin, or Levofloxacin on Chlamydia pneumoniae in a Continuous-Infection Model Antimicrob. Agents Chemother., February 1, 2002; 46(2): 409 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Honeybourne, D. Banerjee, J. Andrews, and R. Wise Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy J. Antimicrob. Chemother., July 1, 2001; 48(1): 63 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. von Baum, S. Bottcher, H. Hoffmann, and H.-G. Sonntag Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery J. Antimicrob. Chemother., May 1, 2001; 47(5): 729 - 730. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gotfried, L. H. Danziger, and K. A. Rodvold Steady-State Plasma and Intrapulmonary Concentrations of Levofloxacin and Ciprofloxacin in Healthy Adult Subjects Chest, April 1, 2001; 119(4): 1114 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Piscitelli, K. Spooner, B. Baird, A. T. Chow, C. L. Fowler, R. R. Williams, J. Natarajan, H. Masur, and R. E. Walker Pharmacokinetics and Safety of High-Dose and Extended-Interval Regimens of Levofloxacin in Human Immunodeficiency Virus-Infected Patients Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2323 - 2327. [Abstract] [Full Text]
|
|
|
|
|
|
L. J. V. Piddock, M. Johnson, V. Ricci, and S. L. Hill Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2956 - 2960. [Abstract] [Full Text]
|
|